Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Recalled Omontys Side Effects Now Linked to 22 Deaths October 18, 2013 Irvin Jackson Add Your Comments The side effects of the anemia drug Omontys, recalled after less than a year on the market, may have been far worse than what was initially reported, according to a new analysis.  An Omontys recall was announced earlier this year after an investigation into five deaths that appeared to be caused by lethal allergic reactions. Since then, with the exception of a Wall Street Journal report in March 2013, there has been little word on the drug’s side effects during its short run. The investment website Seeking Alpha began to raise questions after Omontys was recalled in February of this year, as there were no further reports from the manufacturers, Affymax and Takeda Pharmaceuticals, or the FDA. Learn More About Omontys Lawsuit An Omontys recall was issued in Feb. 2013 due to risk of allergic reaction, deaths. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Omontys Lawsuit An Omontys recall was issued in Feb. 2013 due to risk of allergic reaction, deaths. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Probing into the FDA’s adverse event reports, Seeking Alpha reports that it has identified at least 22 deaths that may be related to Omontys side effects, which is substantially more than prior estimates. The report, published on October 14, looked at 107 pages of adverse event reports submitted to the FDA. Omontys Risk of Allergic Reactions Omontys (peginesatide) was introduced in April 2012 for the treatment of anemia in dialysis patients. It was used primarily at Fresenius dialysis centers as part of a pilot program. By August 2012, the FDA was receiving reports of severe and sometimes deadly anaphylaxis reactions to the drug. By February 2013, the manufacturers recalled Omontys after it was determined that the risks outweighed the potential benefits. Initially, only three deaths were announced, but that number was later increased to five. Later reports suggested 12 Omontys deaths may have occurred before the recall. That number has now been increased to 22 deaths. About 25,000 patients were exposed to the drug before the recall. However, adverse event reports submitted to the FDA typically only represent about 1% to 10% of all adverse events actually associated with prescription medications. Among the deaths identified, at least one involved a patient who received a subcutaneous injection, as well as several nonfatal adverse event reports. This is noteworthy because Affymax ex-CEO John Orwin previously denied any such reports existed and claimed the company hoped to reintroduce Omontys as subcutaneous-only drug. Omontys allergic reactions typically began to appear within 30 minutes of the first injection, which is designed to be given once per month. According to information previously released by Affymax and Takeda, the Omontys problems occurred in about 0.2% of cases, with about a third of those being serious and sometimes including anaphylaxis that requires prompt medical intervention and hospitalization. Fatal reactions occur in about 0.02% of all cases, according to the manufacturers. Tags: Affymax, Allergic Reaction, Anemia, Dialysis, Fresenius, Omontys, Takeda Pharmaceuticals Image Credit: | More Omontys Lawsuit Stories Omontys Problems Likely Signal End for Drug Maker: Analysts November 15, 2013 Omontys Allergic Reaction Problems Appeared Soon After Drug Approved April 2, 2013 Omontys Recall Issued Due to Deaths, Anaphylaxis Reactions February 25, 2013 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 3 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025) Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: 4 days ago) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025) BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: 5 days ago) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025)
MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 3 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)
Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: 4 days ago) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)
BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: 5 days ago) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025)